Share Name Share Symbol Market Type Share ISIN Share Description
BB Healthcare LSE:BBH London Ordinary Share GB00BZCNLL95 RED ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.21% 118.00p 117.75p 118.25p 118.25p 117.75p 118.25p 197,519 12:32:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 304.23

BB Healthcare (BBH) Latest News (1)

More BB Healthcare News
BB Healthcare Takeover Rumours

BB Healthcare (BBH) Share Charts

1 Year BB Healthcare Chart

1 Year BB Healthcare Chart

1 Month BB Healthcare Chart

1 Month BB Healthcare Chart

Intraday BB Healthcare Chart

Intraday BB Healthcare Chart

BB Healthcare (BBH) Discussions and Chat

BB Healthcare Forums and Chat

Date Time Title Posts
24/10/201705:24::: B B HEALTHCARE TRUST :::44
12/7/200615:01Biotech Holders: the last to Run?15

Add a New Thread

BB Healthcare (BBH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:06:24118.0512,69214,982.89O
12:38:44118.055,1696,102.00O
12:32:08118.00128151.04AT
12:09:35118.0695,000112,157.00O
12:09:33117.751,5421,815.71AT
View all BB Healthcare trades in real-time

BB Healthcare (BBH) Top Chat Posts

DateSubject
23/11/2017
08:20
BB Healthcare Daily Update: BB Healthcare is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker BBH. The last closing price for BB Healthcare was 118.25p.
BB Healthcare has a 4 week average price of 113.75p and a 12 week average price of 112.75p.
The 1 year high share price is 123.75p while the 1 year low share price is currently 100.50p.
There are currently 257,819,268 shares in issue and the average daily traded volume is 296,358 shares. The market capitalisation of BB Healthcare is £304,226,736.24.
13/8/2005
07:38
energyi: WAIT ON BIOTECHS DESPITE RECENT STRENGTH by Bruce Zaro August 12, 2005 With investor optimism toward the stock market returning, I felt it appropriate to write a follow-up to my most recent article, ¡§Semiconductors Confirming Economic Strength,¡¨ by highlighting another high-octane sector of the market. Biotechnology stocks capture investors¡¦ hopes and fears like no other group, save Internet stocks. As people search for the company that will provide the cure for cancer, AID, etc. and it¡¦s no shock that the cycle of promise and disappointment in this sector can result in a $1.13 stock that runs up to $3.50 Tuesday and settles back to $1.20 by Friday. Indeed, the biotech sector as a whole thus far in 2005 has shown a first quarter performance of negative 9.9% while the second quarter rebounded to show a 12.5% gain. Love ¡¥em and hate ¡¥em all in the same year: that¡¦s the biotech group. Because this sector can be so volatile, I believe it is possible to be a little bit late to the party and still catch significant percentage moves in individual biotech issues. Thus, I tend to hold biotech stocks in our portfolios only when they clearly show signs of sponsorship and particularly when they¡¦re exhibiting such strength from oversold levels. And since this volatile sector can provide buying opportunities and significant profit taking opportunities in short order, it is wisest for most investors to steer toward the large, liquid biotech names such as Gilead, Amgen and Genentech while avoiding the flash-in-the-pan types like Entremed and Ariad, despite their momentary allure. Further, my investment management style is firmly based on the premise that when investing, market conditions are most important in determining when to act, followed by the sector¡¦s condition and only lastly by individual stock selection. This classic ¡§top-down¡¨ approach to technical analysis is crucial since studies have shown that market and sector conditions typically account for more than 75% of a stock¡¦s movement, with only a fraction of share price movement actually coming from the company¡¦s fundamentals itself. Because I so highly value market and sector conditions when analyzing what to buy, perhaps a look at whether the Biotech sector currently makes sense is in order. While the market is currently on the offensive, from a supply and demand standpoint it is in relatively poor field position and the rally from the May lows is getting tired. Recently, there have been some early signs that the summer dog days are starting to set in. Because we reach such posture in front of the often-troubling months of September and October, I am expecting any pullback we might see in those months to provide an attractive entry point. Because the Biotech sector relative strength is strong and getting stronger, it will be one of the groups I¡¦ll have my eye on in coming weeks. As can be seen in the chart below, the sector bullish percentage recently exceeded its previous top at 50 (most recent column of Xs, which mark rising trends in Point and Figure analysis): @: http://www.financialsense.com/fsu/editorials/2005/0812.html
BB Healthcare share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20171123 13:24:42